Evogene Stock Price, News & Analysis

Evogene Ltd. (EVGN) is a computational biology and chemistry company that applies big data and artificial intelligence to the discovery and development of life‑science based products. According to the company’s disclosures, Evogene focuses on improving the probability of success in R&D while reducing development time and cost, with activities spanning the pharmaceutical and agricultural industries.

Evogene’s shares trade on Nasdaq and the Tel Aviv Stock Exchange under the symbol EVGN. The company describes itself as aiming to revolutionize life‑science product discovery and development by combining advanced computational platforms with deep multidisciplinary understanding in life sciences.

Core technology and tech‑engines

Evogene has established three proprietary technology engines, referred to as MicroBoost AI, ChemPass AI and GeneRator AI. Each tech‑engine is focused on products built from a specific type of core component:

• MicroBoost AI – focused on microbes.
• ChemPass AI – focused on small molecules.
• GeneRator AI – focused on genetic elements.

These tech‑engines use big data and AI‑driven computational methods to support product discovery and optimization. Evogene uses them both in its own operations and through subsidiaries and collaborations.

ChemPass AI and generative small‑molecule design

A central pillar of Evogene’s current strategy is ChemPass AI, its proprietary tech‑engine for small molecule discovery and optimization. The company describes ChemPass AI as a generative AI engine or tech‑engine that designs novel, highly potent small molecules optimized across multiple critical parameters. Evogene states that this approach is intended to significantly improve success rates in small‑molecule discovery while reducing development time and costs.

Evogene has also reported the completion of a generative AI foundation model for small‑molecule design, developed in collaboration with Google Cloud, and trained on a large dataset of molecular structures. According to the company, this foundation model expands ChemPass AI’s capabilities by enabling simultaneous consideration of complex product requirements and the generation of new molecular structures for pharmaceutical and agriculture applications.

Application areas: pharma and agriculture

Evogene positions itself at the intersection of pharmaceuticals and agriculture. In multiple disclosures, the company describes a focus on creating novel small molecules for the pharmaceutical and ag‑chemical industries, and more broadly on life‑science based products in these markets.

On the pharmaceutical side, Evogene reports collaborations aimed at discovering and optimizing small‑molecule therapeutics. Examples include a collaboration with Unravel Biosciences to design brain‑penetrant small molecules for remyelination in demyelinating diseases, and a collaboration with a research group at Tel Aviv University to develop small molecules targeting metabolite self‑assembly in metabolic diseases such as Tyrosinemia and Gout. In these collaborations, ChemPass AI is used for generative molecular design and multi‑parameter optimization of candidate molecules.

On the agriculture side, Evogene uses ChemPass AI and its broader tech‑engine suite to support crop protection and agricultural innovation. The company has described integrating the activities of its ag‑chemicals subsidiary AgPlenus into Evogene to enhance the application of ChemPass AI in crop protection. Evogene has also highlighted Casterra Ag Ltd., a subsidiary that develops high‑yield castor seed varieties and advanced castor farming systems for bio‑based industries, which leverages genomic capabilities licensed from Evogene.

Subsidiary structure and partnerships

Evogene’s business model includes both internal development and work through subsidiaries and strategic partners. The company has disclosed several key subsidiaries that utilize its tech‑engines:

• Biomica Ltd. – develops and advances microbiome‑based therapeutics for human disorders, powered by MicroBoost AI.
• Lavie Bio Ltd. – develops and commercially advances microbiome‑based ag‑biologicals, powered by MicroBoost AI. Evogene has announced the completion of a transaction in which most of Lavie Bio’s activity and assets were sold to ICL Group Ltd., while certain existing strategic partnerships and commercial agreements remain with Lavie Bio.
• AgPlenus Ltd. – develops next‑generation ag‑chemicals for crop protection, powered by ChemPass AI. Evogene has described plans to integrate AgPlenus’ activities into Evogene to align agricultural offerings around ChemPass AI.
• Casterra Ag Ltd. – develops and markets superior castor seed varieties and integrated castor farming systems for biofuel and other bio‑based industries, using genomic capabilities licensed from Evogene and powered by GeneRator AI.

Evogene reports that it develops products through strategic partnerships and collaborations as well as via these subsidiaries. Examples include collaborations with academic institutions, such as Tel Aviv University, and with industry partners in both pharma and agriculture.

Strategic focus and corporate repositioning

Evogene has described a strategic repositioning around ChemPass AI as its core engine. In its communications, the company emphasizes a unified corporate focus on ChemPass AI serving two main verticals:

• Pharma – discovery of novel small‑molecule therapeutics.
• Agriculture – crop protection innovation and related ag‑tech applications.

The company has also reported cost‑reduction and restructuring measures, including workforce reductions and the sale of most of Lavie Bio’s activity and the MicroBoost AI for Ag platform to ICL. These steps are presented by Evogene as part of a move toward a more focused, AI‑centric business centered on ChemPass AI and selected subsidiaries.

Industry classification and stock information

For industry classification purposes, Evogene is associated with the Pesticide and Other Agricultural Chemical Manufacturing industry within the broader manufacturing sector, reflecting the agricultural and ag‑chemical dimension of its activities. At the same time, the company’s own descriptions emphasize its role as a computational biology and chemistry company using AI and big data for life‑science product development.

Evogene’s ordinary shares are listed on Nasdaq and on the Tel Aviv Stock Exchange under the ticker EVGN. The company files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, including Form 20‑F and periodic Form 6‑K reports that furnish financial statements, operating and financial reviews, and information on corporate actions and transactions.

Use cases for investors and analysts

Investors and analysts examining EVGN often focus on the progress and adoption of Evogene’s tech‑engines, particularly ChemPass AI, the status of key collaborations in pharma and agriculture, and the performance and strategic direction of its subsidiaries. Regulatory filings and company news provide insight into Evogene’s restructuring steps, asset sales, collaboration agreements, and ongoing financial position.